News Releases

Month Year

Month Year

Investor Alerts

Jul 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August
Jul 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
Jun 22, 2020

Immunic, Inc. to Join Russell 3000® Index
Jun 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
Jun 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock

Show per page

f